PMID- 14671086
OWN - NLM
STAT- MEDLINE
DCOM- 20040120
LR  - 20201208
IS  - 0022-538X (Print)
IS  - 1098-5514 (Electronic)
IS  - 0022-538X (Linking)
VI  - 78
IP  - 1
DP  - 2004 Jan
TI  - Identification and characterization of novel, naturally processed measles virus 
      class II HLA-DRB1 peptides.
PG  - 42-51
AB  - Previously, we identified a naturally processed and presented measles virus (MV) 
      19-amino-acid peptide, ASDVETAEGGEIHELLRLQ (MV-P), derived from the 
      phosphoprotein and eluted from the human leukocyte antigen (HLA) class II 
      molecule by using mass spectrometry. We report here the identification of a 
      14-amino-acid peptide, SAGKVSSTLASELG, derived from the MV nucleoprotein (MV-N) 
      bound to HLA-DRB1*0301. Peripheral blood mononuclear cells (PBMC) from 281 
      previously vaccinated measles-mumps-rubella II (MMR-II) subjects (HLA discordant) 
      were studied for peptide recognition by T cells. Significant gamma interferon 
      (IFN-gamma) responses to MV-P and MV-N peptides were observed in 55.9 and 15.3% 
      of subjects, respectively. MV-P- and MV-N-specific interleukin-4 (IL-4) responses 
      were detected in 19.2 and 23.1%, respectively, of PBMC samples. Peptide-specific 
      cytokine responses and HLA-DRB1 allele associations revealed that, for the MV-P 
      peptide, the allele with the strongest association with both IFN-gamma (P = 0.02) 
      and IL-4 (P = 0.03) secretion was DRB1*0301. For MV-N, the allele with the 
      strongest association with IFN-gamma secretion was DRB1*1501 (P = 0.04), and the 
      alleles with the strongest associations with IL-4 secretion were DRB1*1103 and 
      DRB1*1303 (P = 0.01). These results indicate that HLA class II MV proteins can be 
      processed, presented, and identified, and the ability to generate cell-mediated 
      immune responses can be demonstrated. This information is promising for new 
      vaccine design strategies with peptide-based vaccines.
FAU - Ovsyannikova, Inna G
AU  - Ovsyannikova IG
AD  - Mayo Vaccine Research Group, Mayo Clinic and College of Medicine, Rochester, 
      Minnesota 55905, USA.
FAU - Johnson, Kenneth L
AU  - Johnson KL
FAU - Muddiman, David C
AU  - Muddiman DC
FAU - Vierkant, Robert A
AU  - Vierkant RA
FAU - Poland, Gregory A
AU  - Poland GA
LA  - eng
GR  - R03 AI053592/AI/NIAID NIH HHS/United States
GR  - AI33144/AI/NIAID NIH HHS/United States
GR  - R01 AI033144/AI/NIAID NIH HHS/United States
GR  - AI53592/AI/NIAID NIH HHS/United States
GR  - R01 AI048793/AI/NIAID NIH HHS/United States
GR  - R37 AI048793/AI/NIAID NIH HHS/United States
GR  - AI48793/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Virol
JT  - Journal of virology
JID - 0113724
RN  - 0 (Cytokines)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*03:01 antigen)
RN  - 0 (Measles-Mumps-Rubella Vaccine)
RN  - 0 (Nucleocapsid Proteins)
RN  - 0 (Nucleoproteins)
RN  - 0 (Peptides)
RN  - 0 (Viral Proteins)
RN  - 0 (nucleoprotein, Measles virus)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Alleles
MH  - Cytokines/biosynthesis/genetics
MH  - HLA-DR Antigens/chemistry/*metabolism
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Interferon-gamma/biosynthesis/genetics
MH  - Interleukin-4/biosynthesis/genetics
MH  - Measles/immunology/prevention & control
MH  - Measles virus/*immunology/metabolism
MH  - Measles-Mumps-Rubella Vaccine/administration & dosage
MH  - Nucleocapsid Proteins
MH  - *Nucleoproteins/chemistry/immunology/metabolism
MH  - *Peptides/chemical synthesis/chemistry/immunology/metabolism
MH  - T-Lymphocytes/immunology
MH  - *Viral Proteins/chemistry/immunology/metabolism
PMC - PMC303425
EDAT- 2003/12/13 05:00
MHDA- 2004/01/21 05:00
PMCR- 2004/01/01
CRDT- 2003/12/13 05:00
PHST- 2003/12/13 05:00 [pubmed]
PHST- 2004/01/21 05:00 [medline]
PHST- 2003/12/13 05:00 [entrez]
PHST- 2004/01/01 00:00 [pmc-release]
AID - 1717 [pii]
AID - 10.1128/jvi.78.1.42-51.2004 [doi]
PST - ppublish
SO  - J Virol. 2004 Jan;78(1):42-51. doi: 10.1128/jvi.78.1.42-51.2004.